Elanco Animal Health Beheer

Beheer criteriumcontroles 3/4

De CEO Elanco Animal Health is Jeff Simmons, benoemd in Jul2018, heeft een ambtstermijn van 6.33 jaar. De totale jaarlijkse vergoeding van { bedraagt $ 13.66M, bestaande uit 8.8% salaris en 91.2% bonussen, inclusief aandelen en opties van het bedrijf. bezit rechtstreeks 0.23% van de aandelen van het bedrijf, ter waarde € 14.38M. De gemiddelde ambtstermijn van het managementteam en de raad van bestuur bedraagt respectievelijk 5.9 jaar en 5.7 jaar.

Belangrijke informatie

Jeff Simmons

Algemeen directeur

US$13.7m

Totale compensatie

Percentage CEO-salaris	8.8%
Dienstverband CEO	6.3yrs
Eigendom CEO	0.2%
Management gemiddelde ambtstermijn	5.9yrs
Gemiddelde ambtstermijn bestuur	5.7yrs

Recente managementupdates

Recent updates

Analyse CEO-vergoeding

Hoe is Jeff Simmons's beloning veranderd ten opzichte van Elanco Animal Health's winst?
Datum	Totale vergoeding	Salaris	Bedrijfswinsten
Sep 30 2024	n/a	n/a	US$205m
Jun 30 2024	n/a	n/a	-US$1b
Mar 31 2024	n/a	n/a	-US$1b
Dec 31 2023	US$14m	US$1m	-US$1b
Sep 30 2023	n/a	n/a	-US$1b
Jun 30 2023	n/a	n/a	-US$113m
Mar 31 2023	n/a	n/a	-US$26m
Dec 31 2022	US$13m	US$1m	-US$78m
Sep 30 2022	n/a	n/a	-US$132m
Jun 30 2022	n/a	n/a	-US$171m
Mar 31 2022	n/a	n/a	-US$371m
Dec 31 2021	US$12m	US$1m	-US$483m
Sep 30 2021	n/a	n/a	-US$698m
Jun 30 2021	n/a	n/a	-US$729m
Mar 31 2021	n/a	n/a	-US$572m
Dec 31 2020	US$9m	US$1m	-US$574m
Sep 30 2020	n/a	n/a	-US$246m
Jun 30 2020	n/a	n/a	-US$101m
Mar 31 2020	n/a	n/a	-US$13m
Dec 31 2019	US$16m	US$1m	US$68m
Sep 30 2019	n/a	n/a	US$94m
Jun 30 2019	n/a	n/a	US$144m
Mar 31 2019	n/a	n/a	US$45m
Dec 31 2018	US$5m	US$775k	US$87m
Sep 30 2018	n/a	n/a	-US$91m
Jun 30 2018	n/a	n/a	-US$172m
Mar 31 2018	n/a	n/a	-US$174m
Dec 31 2017	US$5m	US$688k	-US$311m

Compensatie versus markt: De totale vergoeding ($USD 13.66M ) Jeff } ligt boven het gemiddelde voor bedrijven van vergelijkbare omvang in de German markt ($USD 3.59M ).

Compensatie versus inkomsten: De vergoeding van Jeff is het afgelopen jaar in lijn geweest met de bedrijfsprestaties.

CEO

Jeff Simmons (57 yo)

6.3yrs

Tenure

US$13,663,169

Compensatie

Mr. Jeffrey N. Simmons, also known as Jeff, serves as President and Chief Executive Officer at Elanco Animal Health Incorporated since July 2018 and its Director since September 2018. Mr. Simmons serves as...

Leiderschapsteam

Naam	Positie	Tenure	Compensatie	Eigendom
Jeffrey Simmons	President	6.3yrs	US$13.66m	0.23% € 14.4m
Todd Young	Executive VP & CFO	6yrs	US$3.73m	0.035% € 2.2m
Ramiro Cabral	Executive Vice President of Elanco International	6.3yrs	US$2.65m	0.022% € 1.4m
Ellen de Brabander	Executive Vice President of Research	3.1yrs	US$3.68m	0.0097% € 612.7k
Timothy Bettington	Executive Vice President of Corporate Strategy & Market Development	1.7yrs	US$2.19m	0.017% € 1.1m
James Meer	Senior VP & Chief Accounting Officer	6.2yrs	geen gegevens	0.0054% € 345.0k
Chris Keeley	Senior VP & Chief Information Officer	no data	geen gegevens	geen gegevens
David Kinard	Executive Vice President of Human Resources	5.8yrs	US$2.85m	0.024% € 1.5m
Katy Grissom	Head of Investor Relations	no data	geen gegevens	geen gegevens
Shiv O'Neill	Executive Vice President	1.8yrs	geen gegevens	0.0048% € 305.1k
Larbi Lier	Senior Vice President of Asia	no data	geen gegevens	geen gegevens
Shabbir Simjee	Chief Medical Officer	no data	geen gegevens	geen gegevens

5.9yrs

Gemiddelde duur

53yo

Gemiddelde leeftijd

Ervaren management: Het managementteam van 5EA is doorgewinterd en ervaren (gemiddelde ambtstermijn van 5.9 jaar).

Bestuursleden

Naam	Positie	Tenure	Compensatie	Eigendom
Jeffrey Simmons	President	6.2yrs	US$13.66m	0.23% € 14.4m
William Doyle	Independent Director	3.9yrs	US$330.01k	0.0061% € 385.0k
Roy Hoover	Independent Director	6.2yrs	US$496.01k	0.060% € 3.8m
Paul Herendeen	Independent Director	3.9yrs	US$330.01k	0.0020% € 128.1k
Lawrence Kurzius	Independent Chairman	6.2yrs	US$350.01k	0.0020% € 128.1k
Art Garcia	Independent Director	5.5yrs	US$330.01k	0.00071% € 45.0k
Denise Scots-Knight	Independent Director	5.7yrs	US$330.01k	geen gegevens
John Paul Bilbrey	Independent Director	5.7yrs	US$346.01k	0.0084% € 535.3k
Deborah Kochevar	Independent Director	5.7yrs	US$346.01k	0.00020% € 12.7k
Kirk McDonald	Independent Director	5.7yrs	US$330.01k	geen gegevens
Michael Harrington	Independent Director	6.2yrs	US$330.01k	0.0040% € 251.2k
Kapila Anand	Independent Director	6.2yrs	US$355.01k	0.00065% € 41.2k

5.7yrs

Gemiddelde duur

65.5yo

Gemiddelde leeftijd

Ervaren bestuur: De raad van bestuur van 5EA wordt beschouwd als ervaren (gemiddelde ambtstermijn 5.7 jaar).

Elanco Animal Health Beheer

Beheer criteriumcontroles 3/4

Belangrijke informatie

Recente managementupdates

Elanco Animal Health Incorporated Appoints Stacey Ma as Board of Directors

President recently bought €1.2m worth of stock

Elanco Animal Health Incorporated, Annual General Meeting, May 30, 2024

Elanco Animal Health Incorporated Appoints Kathy Turner and Craig Wallace, to Its Board of Directors

Elanco Animal Health Incorporated Appoints Shiv O'Neill as Executive Vice President, General Counsel and Corporate Secretary

Elanco Animal Health Incorporated Announces Executive Changes

Recent updates

Elanco Animal Health Incorporated Appoints Stacey Ma as Board of Directors

New major risk - Revenue and earnings growth

Elanco Animal Health Incorporated Provides Earnings Guidance for the Fourth Quarter 2024

Third quarter 2024 earnings released: EPS: US$0.74 (vs US$2.22 loss in 3Q 2023)

Elanco Animal Health Incorporated to Report Q3, 2024 Results on Nov 07, 2024

Bragar Eagel & Squire, P.C. Files Class Action Lawsuit Against Elanco Animal Health Incorporated

Elanco Animal Health Incorporated Receives FDA Approval for Credelio Quattro, the Broadest(i) Canine Oral Parasiticide Protection in a Single Monthly Dose

President recently bought €1.2m worth of stock

Second quarter 2024 earnings released: US$0.10 loss per share (vs US$0.20 loss in 2Q 2023)

Elanco Animal Health Incorporated Raises Earnings Guidance for the Full Year 2024

Elanco Animal Health Incorporated to Report Q2, 2024 Results on Aug 08, 2024

Intervet International B.V. completed the acquisition of Assets of Aqua Business from Elanco Animal Health Incorporated (NYSE:ELAN).

Elanco Provides Innovation Update

Forecast to breakeven in 2025

Elanco Animal Health Incorporated Announces FDA Completed Review of Bovaer®, First-in-Class Methane-Reducing Feed Ingredient, for U.S. Dairy Industry

Elanco Animal Health Incorporated Updates Earnings Guidance for the Full Year 2024

First quarter 2024 earnings released: EPS: US$0.065 (vs US$0.21 in 1Q 2023)

Elanco Animal Health Incorporated Updates Earnings Guidance for the Second Quarter and Full Year 2024

Elanco Animal Health Incorporated, Annual General Meeting, May 30, 2024

Elanco Animal Health Incorporated to Report Q1, 2024 Results on May 08, 2024

Elanco Animal Health Incorporated Appoints Kathy Turner and Craig Wallace, to Its Board of Directors

Elanco Animal Health Incorporated Appoints Shiv O'Neill as Executive Vice President, General Counsel and Corporate Secretary

Elanco Animal Health Incorporated Provides Earnings Guidance for the First Quarter and Full Year 2024

Full year 2023 earnings released: US$2.50 loss per share (vs US$0.16 loss in FY 2022)

Elanco Animal Health Incorporated to Report Q4, 2023 Results on Feb 26, 2024

Elanco Animal Health Incorporated Announces Executive Changes

Insufficient new directors

Forecast to breakeven in 2025

Forecast to breakeven in 2025

Elanco Animal Health Incorporated Provides Financial Guidance for the Fourth Quarter 2023

New major risk - Revenue and earnings growth

Elanco Animal Health Incorporated to Report Q3, 2023 Results on Nov 07, 2023

Elanco Animal Health Incorporated(NYSE:ELAN) dropped from FTSE All-World Index (USD)

No longer forecast to breakeven

Elanco Animal Health Incorporated Launches Varenzin-CA1 (Molidustat Oral Suspension) - the First-Of-Its-Kind Oral Treatment for Anemia in Cats with Chronic Kidney Disease

New minor risk - Profitability

No longer forecast to breakeven

Forecast to breakeven in 2024

Second quarter 2023 earnings released: US$0.20 loss per share (vs US$0.045 loss in 2Q 2022)

First quarter 2023 earnings released: EPS: US$0.21 (vs US$0.098 in 1Q 2022)

Elanco Animal Health Incorporated Raises Earnings Guidance for the First Half and Full Year 2023

Forecast breakeven date pushed back to 2025

President recently bought €135k worth of stock

Independent Chairman of the Board recently bought €105k worth of stock

Full year 2022 earnings released: US$0.15 loss per share (vs US$0.97 loss in FY 2021)

Forecast breakeven date pushed back to 2024

Elanco Animal Health Incorporated to Report Q4, 2022 Results on Feb 21, 2023

Elanco Animal Health Incorporated Announces FDA Approval of Bexacat(TM) (bexagliflozin tablets) -- the First-of-its Kind Oral Feline Diabetes Treatment Option

Independent Director recently bought €96k worth of stock

Third quarter 2022 earnings released: US$0.10 loss per share (vs US$0.21 loss in 3Q 2021)

Elanco Animal Health Incorporated Provides Earnings Guidance for the Year 2022

Elanco Animal Health Incorporated to Report Q3, 2022 Results on Nov 08, 2022

Insider recently bought €150k worth of stock

Scott Ferguson Steps Down from the Board of Directors of Elanco Animal Health Incorporated

Elanco Animal Health Incorporated Provides Earnings Guidance for Third Quarter of 2022

Second quarter 2022 earnings released: US$0.045 loss per share (vs US$0.43 loss in 2Q 2021)

Elanco Animal Health Incorporated to Report Q2, 2022 Results on Aug 08, 2022

Independent Chairman of the Board recently bought €221k worth of stock

Independent Director recently bought €209k worth of stock

First quarter 2022 earnings released: EPS: US$0.098 (vs US$0.13 loss in 1Q 2021)

Elanco Animal Health Updates Guidance for the Full Year of 2022

Elanco Animal Health Incorporated to Report Q1, 2022 Results on May 09, 2022

Elanco Animal Health Incorporated, Annual General Meeting, May 18, 2022

Independent Chairman of the Board recently bought €260k worth of stock

Full year 2021 earnings: Revenues and EPS in line with analyst expectations

Elanco Animal Health Incorporated Provides Earnings Guidance for the First Quarter and Full Year of 2022

Elanco Animal Health Incorporated Announces Appointment of Rajeev (Bobby) Modi as its Executive Vice President U.S. Pet Health and Global Digital Transformation

TriRx Pharmaceutical Services, LLC acquired Elanco Manufacturing Facility in Speke from Elanco Animal Health Incorporated (NYSE:ELAN).

Elanco Adds New Tools to Advance U.S. Livestock Sustainability Efforts